AdipoRon exerts opposing effects on insulin sensitivity via fibroblast growth factor 21–mediated time-dependent mechanisms

Yongliang Wang, Huan Liu, Ruixin Zhang, Yuyao Xiang, Junfeng Lu, Bo Xia, Liang Peng, Jiangwei WuJournal of Biological Chemistry 2022 · DOI

Abstract

Increasing evidence has shown that AdipoRon, a synthetic adiponectin receptor agonist, is involved in the regulation of whole-body insulin sensitivity and energy homeostasis. However, the mechanisms underlying these alterations remain unclear. Here, using hyperinsulinemic–euglycemic clamp and isotopic tracing techniques, we show that short-term (10 days) AdipoRon administration indirectly inhibits lipolysis in white adipose tissue via increasing circulating levels of fibroblast growth factor 21 in mice fed a high-fat diet. This led to reduced plasma-free fatty acid concentrations and improved lipid-induced whole-body insulin resistance. In contrast, we found that long-term (20 days) AdipoRon administration directly exacerbated white adipose tissue lipolysis, increased hepatic gluconeogenesis, and impaired the tricarboxylic acid cycle in the skeletal muscle, resulting in aggravated whole-body insulin resistance. Together, these data provide new insights into the comprehensive understanding of multifaceted functional complexity of AdipoRon. Increasing evidence has shown that AdipoRon, a synthetic adiponectin receptor agonist, is involved in the regulation of whole-body insulin sensitivity and energy homeostasis. However, the mechanisms underlying these alterations remain unclear. Here, using hyperinsulinemic–euglycemic clamp and isotopic tracing techniques, we show that short-term (10 days) AdipoRon administration indirectly inhibits lipolysis in white adipose tissue via increasing circulating levels of fibroblast growth factor 21 in mice fed a high-fat diet. This led to reduced plasma-free fatty acid concentrations and improved lipid-induced whole-body insulin resistance. In contrast, we found that long-term (20 days) AdipoRon administration directly exacerbated white adipose tissue lipolysis, increased hepatic gluconeogenesis, and impaired the tricarboxylic acid cycle in the skeletal muscle, resulting in aggravated whole-body insulin resistance. Together, these data provide new insights into the comprehensive understanding of multifaceted functional complexity of AdipoRon. Adiponectin, a cytokine produced by adipocytes (1Scherer P.E. Williams S. Fogliano M. Baldini G. Lodish H.F. A novel serum protein similar to C1q, produced exclusively in adipocytes.J. Biol. Chem. 1995; 270: 26746-26749Google Scholar), acts as a protective regulator because of its antilipotoxic, anti-inflammatory, and antiapoptotic properties (2Holland W.L. Scherer P.E. Cell Biology. Ronning after the adiponectin receptors.Science. 2013; 342: 1460-1461Google Scholar). However, its expression levels are significantly decreased in obesity (3Arita Y. Kihara S. Ouchi N. Takahashi M. Maeda K. Miyagawa J.-i. Hotta K. Shimomura I. Nakamura T. Miyaoka K. Kuriyama H. Nishida M. Yamashita S. Okubo K. Matsubara K. et al.Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity.Biochem. Biophys. Res. Commun. 1999; 257: 79-83Google Scholar) and type 2 diabetes (4Hotta K. Funahashi T. Arita Y. Takahashi M. Matsuda M. Okamoto Y. Iwahashi H. Kuriyama H. Ouchi N. Maeda K. Nishida M. Kihara S. Sakai N. Nakajima T. Hasegawa K. et al.Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients.Arterioscler. Thromb. Vasc. Biol. 2000; 20: 1595-1599Google Scholar). Adiponectin administration is reported to ameliorate insulin resistance and glucose intolerance via activating the 5′ adenosine monophosphate–activated protein kinase (AMPK) (5Yamauchi T. Kamon J. Minokoshi Y. Ito Y. Waki H. Uchida S. Yamashita S. Noda M. Kita S. Ueki K. Eto K. Akanuma Y. Froguel P. Foufelle F. Ferre P. et al.Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase.Nat. Med. 2002; 8: 1288-1295Google Scholar, 6Tomas E. Tsao T.-S. Saha A.K. Murrey H.E. Zhang C.c. Itani S.I. Lodish H.F. Ruderman N.B. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: Acetyl–CoA carboxylase inhibition and AMP-activated protein kinase activation.Proc. Natl. Acad. Sci. U. S. A. 2002; 99: 16309-16313Google Scholar) and peroxisome proliferator–activated receptor α (PPARα) pathways (7Kersten S. Desvergne B. Wahli W. Roles of PPARs in health and disease.Nature. 2000; 405: 421-424Google Scholar) by binding to adiponectin receptor 1 and adiponectin receptor 2, respectively (8Yamauchi T. Nio Y. Maki T. Kobayashi M. Takazawa T. Iwabu M. Okada-Iwabu M. Kawamoto S. Kubota N. Kubota T. Ito Y. Kamon J. Tsuchida A. Kumagai K. Kozono H. et al.Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions.Nat. Med. 2007; 13: 332-339Google Scholar). Despite the beneficial effects of adiponectin on the regulation of metabolism and energy homeostasis, its complicated structure and rapid turnover limit its clinical application (2Holland W.L. Scherer P.E. Cell Biology. Ronning after the adiponectin receptors.Science. 2013; 342: 1460-1461Google Scholar). AdipoRon, an orally active synthetic small molecule, was identified as adiponectin receptor agonist that can bind to and activate both adiponectin receptor 1 and adiponectin receptor 2 (9Okada-Iwabu M. Iwabu M. Ueki K. Yamauchi T. Kadowaki T. Perspective of small-molecule AdipoR agonist for type 2 diabetes and short life in obesity.Diabetes Metab. J. 2015; 39: 363-372Google Scholar). Similar to adiponectin, AdipoRon has many beneficial properties as a novel therapeutic agent for the treatment of metabolic-related diseases, such as type 2 diabetic nephropathy, via the activation of the Ca2+/liver kinase B1–AMPK/PPARα pathway (10SR C. JH L. MY K. EN K. Y K. BS C. YS K. HW K. KM L. MJ K. CW P. Adiponectin receptor agonist AdipoRon decreased ceramide, and lipotoxicity, and ameliorated diabetic nephropathy.Metabolism. 2018; 85: 348-360Google Scholar, 11Iwabu M. Okada-Iwabu M. Yamauchi T. Kadowaki T. Adiponectin/AdipoR research and its implications for lifestyle-related diseases.Front. Cardiovasc. Med. 2019; 6: 116Google Scholar). AdipoRon also plays a protective role in cardiac hypertrophy partly by activating AMPK-related pathways (12Hu X. Ou-Yang Q. Wang L. Li T. Xie X. Liu J. AdipoRon prevents l-thyroxine or isoproterenol-induced cardiac hypertrophy through regulating the AMPK-related pathway.Acta Biochim. Biophys. Sin. (Shanghai). 2018; 51: 20-30Google Scholar). Recent studies have demonstrated that oral administration or intraperitoneal injection of AdipoRon protects against postischemic myocardial apoptosis and secondary brain injury after intracerebral hemorrhage, which is possibly mediated by AMPK signaling (13Zhang Y. Zhao J. Li R. Lau W.B. Yuan Y.X. Liang B. Li R. Gao E.H. Koch W.J. Ma X.L. Wang Y.J. AdipoRon, the first orally active adiponectin receptor activator, attenuates postischemic myocardial apoptosis through both AMPK-mediated and AMPK-independent signalings.Am. J. Physiol. Endocrinol. Metab. 2015; 309: E275-E282Google Scholar, 14Yu J. Zheng J. Lu J. Sun Z. Wang Z. Zhang J. AdipoRon protects against secondary brain injury after intracerebral hemorrhage via alleviating mitochondrial dysfunction: Possible involvement of AdipoR1-AMPK-PGC1α pathway.Neurochem. Res. 2019; 44: 1678-1689Google Scholar). In addition, a recent study has shown that oral administration of AdipoRon for 10 days increased fatty acid combustion and decreased oxidative stress and lipotoxicity in skeletal muscle and liver, which collectively improved insulin sensitivity and ameliorated glucose intolerance, thereby prolonging the shortened life span of diabetic mice (15Okada-Iwabu M. Yamauchi T. Iwabu M. Honma T. Hamagami K. Matsuda K. Yamaguchi M. Tanabe H. Kimura-Someya T. Shirouzu M. Ogata H. Tokuyama K. Ueki K. Nagano T. Tanaka A. et al.A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity.Nature. 2013; 503: 493-499Google Scholar). Hence, AdipoRon has been proposed as a potent energy regulator for the treatment of metabolic diseases. However, available data do not provide systemic mechanism underlying AdipoRon-mediated glucose homoeostasis, and whether the action of AdipoRon effectively and sustainably contributes to systemic energy homoeostasis is unclear. In this study, we applied the hyperinsulinemic–euglycemic clamping method to assess whole-body insulin sensitivity of mice following short-term and long-term AdipoRon administration. The results showed that hepatic fibroblast growth factor 21 (FGF21) is linked to short-term AdipoRon-induced hepatic PPARα activation (10-day subcutaneous injection at 5 mg kg−1 body weight [BW] per day), which improved glucose and lipid metabolism. Briefly, AdipoRon activates AdipoR–PPARα signaling, which increases hepatic FGF21 synthesis and secretion, leading to the suppression of lipolysis in white adipose tissue (WAT) and subsequent lower plasma levels of free fatty acids (FFAs), thus attenuating lipotoxicity of the liver and muscle and improving whole-body insulin sensitivity. However, long-term (20 days) AdipoRon treatment (5 mg kg−1 BW per day) leads to a high rate of lipolysis in WAT, resulting in aggravated fatty liver and hepatic glucose production. Furthermore, persistent FGF21 activation by AdipoRon results in a sharp increase of circulating FGF21 compared with that in short-term AdipoRon-treated mice, which impairs glucose disposal in the skeletal muscle and subsequently contributes to systemic insulin resistance. To investigate the effects of AdipoRon on high-fat diet (HFD)–induced insulin mice with AdipoRon Despite fat and fat AdipoRon treatment improved whole-body glucose intolerance and and reduced lipid in the liver with protein levels of adipose and the of to in AdipoRon reduced circulating concentrations alterations that AdipoRon lipid and glucose metabolism in mice fed an In contrast, AdipoRon treatment of mice fed the diet on the fat fat glucose levels glucose or hepatic lipid as compared with mice In addition, AdipoRon treatment on protein levels of and the AdipoRon not the glucose rate hyperinsulinemic–euglycemic clamp and showed that AdipoRon-treated mice whole-body glucose disposal in skeletal muscle and glucose in to to mice AdipoRon effects on concentrations and clamping as as suppression and that AdipoRon has on glucose and lipid metabolism of mice fed the with the results of following AdipoRon PPARα protein levels increased in the of mice fed an diet and AdipoRon increased hepatic and circulating FGF21 levels hepatic levels and circulating FGF21 the of AdipoRon on regulation of the pathway in mice was A new of mice and into AdipoRon, and AdipoRon The results showed that AdipoRon treatment plasma FGF21 levels by and decreased lipid in liver and skeletal muscle by and these increases by the of FGF21 with the as by the plasma FGF21 concentrations and lipid of the and AdipoRon 2, to whole-body glucose and the results showed that AdipoRon-induced insulin was by FGF21 not significantly to assess the of the pathway on the of AdipoRon, clamp was AdipoRon-treated mice showed a increase in the improved whole-body insulin resistance. of circulating FGF21 to a to that of the the of AdipoRon 2, and Furthermore, AdipoRon circulating concentrations and clamping which with decreased levels of 1 and involved in However, of AdipoRon-induced FGF21 activation these effects 2, To whether hepatic FGF21 the action of AdipoRon to adipose lipolysis, liver with AdipoRon, and increased PPARα protein levels 2, and adipocytes with with or AdipoRon in the or the of with the in AdipoRon significantly increased the FGF21 concentrations in the of the the FGF21 in the to a similar to that of the lower protein levels of and in the AdipoRon that in the FGF21 the suppression of lipolysis by AdipoRon, as by protein levels of and to of the 2, and Furthermore, lipid was increased in with adipocytes and decreased in FGF21 these as shown by 2, and results that AdipoRon indirectly lipolysis via the activation of the hepatic to ameliorate lipid and whole-body insulin resistance. To in we FGF21 whole-body mice with AdipoRon for 10 days However, BW and and AdipoRon and In addition, clamp studies showed that AdipoRon not as as and whole-body glucose disposal in skeletal muscle showed that AdipoRon also not the of to plasma and the of the of and to AdipoRon-treated mice the of to and with mice in skeletal muscle FGF21 activation linked AdipoRon to lipolysis suppression in WAT, we whether and AdipoRon directly lipid metabolism. of with AdipoRon increased lipid in the AdipoRon as compared with the In addition, the expression levels of the and increased by AdipoRon to and AdipoRon increased the levels of and as as and not and the protein levels of and However, AdipoRon increased the protein levels of and To assess the of AdipoRon on lipolysis, muscle with adipocytes with AdipoRon, or AdipoRon FGF21 FGF21 concentrations in the of lipid was increased in both and and AdipoRon adipocytes as shown by and AdipoRon per can directly To the of AdipoRon on insulin using we the mice with AdipoRon. However, in was found and AdipoRon demonstrated that AdipoRon not whole-body glucose and clamp as as suppression Together, these data that not AdipoRon administration whole-body insulin resistance via hepatic suppression of lipolysis in mice fed the the long-term of AdipoRon on systemic glucose was by mice fed the with AdipoRon for days with long-term AdipoRon administration increased circulating FGF21 concentrations by decreased FGF21 to a to that of mice found that AdipoRon, of circulating FGF21 significantly increased the BW of mice in the AdipoRon and AdipoRon increased was in the AdipoRon and AdipoRon after days of is for the regulation of concentrations similar the thereby the involvement of in AdipoRon-induced in and concentrations these long-term AdipoRon treatment increased lipid in liver by as as in muscle by glucose and hepatic and In to improved insulin sensitivity by short-term AdipoRon the was by long-term as by intraperitoneal studies and To into insulin clamping was which showed significantly decreased in the long-term AdipoRon treatment the insulin action of AdipoRon, as by in the of and in the AdipoRon and AdipoRon respectively and showed that clamp was increased by and suppression was reduced by and in the AdipoRon and AdipoRon respectively and with in clamp or suppression the AdipoRon and AdipoRon AdipoRon reduced glucose disposal by the this AdipoRon increased clamp concentrations of which was with increased expression levels of the and in and AdipoRon treatment reduced glucose of or the tricarboxylic acid cycle was in the skeletal To this we metabolic in skeletal muscle AdipoRon increased the of the of to decreased the of to the of to plasma and the of the of and to as as the of to and However, FGF21 these To these or AdipoRon-treated mice with or the to 10 and with BW found that AdipoRon increased the of glucose and in the skeletal muscle, decreased the of and an of by AdipoRon the of to However, FGF21 the of these to levels to of the with similar concentrations of the of these we that AdipoRon impairs glucose utilization glucose via the activation of hepatic FGF21 in the skeletal muscle in To the mechanism underlying the of AdipoRon to mitochondrial and subsequent glucose and lipid the metabolic of mice using the metabolic The results showed that long-term AdipoRon treatment decreased not in the and or the rate was decreased in the and energy was significantly reduced in the and not in the was in AdipoRon increased in the and with in in the and and with the increase in and in increases in fat and fat and in Recent have shown that the of diabetes in which has the of with diabetes increased in to in L. Gao P. Zhang M. Z. Zhang Q. Li Y. Zhao Z. X. M. X. Y. Wang L. and of diabetes and in in Scholar), resulting in a health has been in understanding the mechanisms underlying insulin resistance and type 2 treatment remain AdipoRon, an orally synthetic adiponectin receptor agonist, has also been as a novel therapeutic agent for the treatment of type 2 diabetes (15Okada-Iwabu M. Yamauchi T. Iwabu M. Honma T. Hamagami K. Matsuda K. Yamaguchi M. Tanabe H. Kimura-Someya T. Shirouzu M. Ogata H. Tokuyama K. Ueki K. Nagano T. Tanaka A. et al.A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity.Nature. 2013; 503: 493-499Google Scholar). However, the underlying mechanism and whether the of the action of AdipoRon to systemic energy homoeostasis has not been To the action of AdipoRon against metabolic mice with AdipoRon for 10 days to the of short-term application on glucose and lipid metabolism. with the of a study (15Okada-Iwabu M. Yamauchi T. Iwabu M. Honma T. Hamagami K. Matsuda K. Yamaguchi M. Tanabe H. Kimura-Someya T. Shirouzu M. Ogata H. Tokuyama K. Ueki K. Nagano T. Tanaka A. et al.A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity.Nature. 2013; 503: 493-499Google Scholar), AdipoRon improved glucose intolerance, reduced lipid by suppression of lipolysis, and subsequently reduced in In contrast, was in whole-body glucose lipid or levels in mice fed the following treatment with AdipoRon, that AdipoRon glucose and lipid metabolism in with energy not Similar to PPARα protein levels increased in the liver (15Okada-Iwabu M. Yamauchi T. Iwabu M. Honma T. Hamagami K. Matsuda K. Yamaguchi M. Tanabe H. Kimura-Someya T. Shirouzu M. Ogata H. Tokuyama K. Ueki K. Nagano T. Tanaka A. et al.A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity.Nature. 2013; 503: 493-499Google Scholar). PPARα has been identified as a regulator of hepatic lipid metabolism and energy in to P. G. E. fibroblast growth factor 21 is by and is a of hepatic lipid metabolism in Metab. 2007; Scholar) and T. P. Zhao G. X. L. Li Y. R. M. et regulation of the by of fibroblast growth factor Metab. 2007; Scholar). PPARα can directly FGF21 expression and increase circulating FGF21 levels T. P. Zhao G. X. L. Li Y. R. M. et regulation of the by of fibroblast growth factor Metab. 2007; Scholar, T. S. B. M. is a regulator of hepatic Biophys. Res. Commun. 2007; Scholar). AdipoRon administration FGF21 expression as by increased circulating FGF21 concentrations in mice fed the FGF21 has also been as a metabolic as FGF21 has effects in diabetic and FGF21 mice obesity in an A. A. R. J. Li et as a novel metabolic Scholar). Furthermore, FGF21 administration improved whole-body glucose and lipid metabolism via lipolysis suppression J. Zhang M. mechanisms by which FGF21 insulin sensitivity in 2013; Scholar). these data the of whether AdipoRon glucose and lipid metabolism via hepatic circulating FGF21 to the of AdipoRon. with this levels and circulating FGF21 concentrations in mice with AdipoRon. Furthermore, was a in glucose with reduced lipolysis, as with the hyperinsulinemic–euglycemic clamping However, in AdipoRon-treated mice, FGF21 the in glucose which was with lipolysis, that FGF21 is involved in the action of AdipoRon via the inhibition of short-term AdipoRon found in mice was in mice, in to AdipoRon-treated with the in PPARα protein levels also increased in with AdipoRon, that AdipoRon adiponectin To the of the on the of AdipoRon, with AdipoRon with reduced lipolysis in adipocytes and lipid in with increased FGF21 protein in the these alterations by FGF21 to the FGF21 concentrations in that AdipoRon-induced activation of the is for lipolysis these data that not AdipoRon treatment activates hepatic thereby lipolysis in adipose tissue and circulating which to improved fatty liver, decreased gluconeogenesis, and increased insulin sensitivity in The effects of AdipoRon to lipid metabolism in we the of whether AdipoRon directly lipolysis via To this adipocytes with AdipoRon increases in the expression levels of not in the levels of data that AdipoRon plays a role in expression and have on To this adipocytes with AdipoRon with with this was a increase in lipid in the of as by FGF21 concentrations in the in to in lipid the AdipoRon and AdipoRon that AdipoRon the of with to protein these data that AdipoRon can activate the hepatic leading to lipolysis suppression in WAT, to hepatic and AdipoRon can directly increase the of of protein increased FGF21 expression indirectly inhibits these via the the beneficial effects of AdipoRon on energy metabolism short-term and the that AdipoRon to metabolic we of whether AdipoRon sustainably to energy homeostasis. To these mice fed the with AdipoRon for days in the or the of the to circulating FGF21 levels data have that as a regulator of a the brain to A. H. C. effects are mediated by the in Natl. Acad. Sci. U. S. A. 2019; Scholar). In the study, AdipoRon treatment increased and BW in a and AdipoRon also exacerbated whole-body insulin as by decreased whole-body glucose disposal and increased hepatic glucose production. The not the was by FGF21 AdipoRon directly in a increase in lipolysis in of circulating FGF21 as by in Together, the of whole-body insulin resistance by long-term AdipoRon application can by increased by increased lipolysis and subsequent increased and decreased glucose disposal because of cycle by FGF21 activation in the skeletal Despite insulin resistance AdipoRon on glucose which can by the of in hepatic and and subsequent in hepatic glucose production. FGF21 has been as a potent therapeutic agent for insulin FGF21 concentrations increased with P. G. E. fibroblast growth factor 21 is by and is a of hepatic lipid metabolism in Metab. 2007; Scholar), with insulin resistance in the skeletal muscle in Wang Y. A. S. Zhang a acid cycle to glucose in 2018; Scholar), of circulating FGF21 in to energy metabolism short-term AdipoRon-induced FGF21 activation in mice to in AdipoRon-treated was beneficial to whole-body glucose homeostasis, FGF21 activation by long-term AdipoRon treatment in the to in the AdipoRon reduced glucose disposal because of of the metabolic showed that long-term AdipoRon treatment impaired the of to and thus and long-term AdipoRon treatment and a glucose to fat metabolism these results that long-term AdipoRon activates hepatic FGF21 and lipolysis and the cycle and of the cycle in the skeletal muscle, leading to insulin resistance in the skeletal muscle and This also the mechanism of insulin resistance in which hepatic FGF21 activation the utilization of glucose via the suppression of the cycle to glucose to the brain In these data provide new insights into the beneficial effects of adiponectin on glucose metabolism and systemic insulin sensitivity shown in as as the effects of long-term that to a of metabolism and the clinical application of adiponectin and the of Cell the the in and adipocytes and muscle and the muscle of studies in with the of the of mice the of and FGF21 mice the mice a cycle at a of to with free to and an or short-term AdipoRon mice the or for and with or AdipoRon (5 mg kg−1 BW per day) with or the kg−1 BW per day) the 10 days of the long-term AdipoRon mice the or for days and with AdipoRon (5 mg kg−1 BW per day) with or the kg−1 BW per day) for BW was with an and body fat was by to the mice fed the or for in a with the for 1 for to a the mice with BW or 1 BW of and glucose concentrations at and using and levels in FGF21 and levels using as Wang Y. K. N. by which 1 causes insulin resistance in Natl. Acad. Sci. U. S. A. Scholar) and with and using a as Wang Y. K. N. by which 1 causes insulin resistance in Natl. Acad. Sci. U. S. A. Scholar). the AdipoRon treatment AdipoRon, and AdipoRon mice with BW of and at after and for of and by metabolic was to the of plasma glucose and and The of was as the of The cycle by the of glucose and the cycle through or through was as a for and was as a for The was as the of The was as the of the FGF21 mice FGF21 and mice in a with the for 1 the for glucose the mice and skeletal for of and studies by for via Briefly, the mice with in the and for for days the mice to and with at a rate of AdipoRon at a rate of for AdipoRon treatment clamp for glucose for with a of insulin by a insulin and 5 AdipoRon at a rate of for AdipoRon treatment clamp as as a of to the mice with a and the and tissue The tissue in for or in for glucose turnover and glucose as was as Wang Y. A. S. Zhang a acid cycle to glucose in 2018; Scholar). Briefly, 10 of plasma was with of 10 and of 10 and with of and an of at for the was with of was using in The clamp was as of and and in the and of a The with in with AdipoRon or the in the and the in the in with or of for AdipoRon in the of and with as Y. Liu X. L. W. Zhao S. Y. growth factor 21 in fat J. Sci. 2015; Scholar) or the AdipoRon for of adipocytes and muscle and adipocytes mice in the and of a The muscle with as X. Wang Y. L. Y. Zhao S. growth factor 21 (FGF21) of via the Cell Physiol. Scholar), the adipocytes with with or AdipoRon. the muscle in the and the adipocytes in the in with or of for was using a in with the and into with a first and by with a was as Y. Liu Y. F. Sun X. Wang X. Wang Y. whole-body insulin resistance via white adipose tissue lipolysis in Biophys. Res. Commun. Scholar), with a in the in and in and to at at for of protein was into the of and by was to using a for 1 with the with the with secondary for 2 using a and and Cell and was liver in with as Y. Liu X. L. W. Zhao S. Y. growth factor 21 in fat J. Sci. 2015; Scholar). with are as the The was to A was of was for of was for and for and to and by the This The that have of with the of this of for This was by the and of of and of and also the for with Y. B. L. and J. W. Y. H. R. Y. J. and X. Q. Y. H. R. Y. J. and X. Q. Y. W. B. L. and J. W. Y. H. R. Y. J. and X. Q. data Y. W. B. L. and J. W. Y. H. R. Y. J. and X. Q. B. L. and J. W. B. L. and J. W. Y. L. and J. W. AdipoRon treatment has on glucose metabolism in fed of glucose and the whole-body glucose and are as the AdipoRon treatment glucose in skeletal muscle in of and in the skeletal of are as the
BibTeX
@article{wang2022adiporon,
  author = {Yongliang Wang and Huan Liu and Ruixin Zhang and Yuyao Xiang and Junfeng Lu and Bo Xia and Liang Peng and Jiangwei Wu},
  title = {{AdipoRon exerts opposing effects on insulin sensitivity via fibroblast growth factor 21–mediated time-dependent mechanisms}},
  journal = {Journal of Biological Chemistry},
  year = {2022},
  doi = {10.1016/j.jbc.2022.101641},
}

Loading related content...

Figure